Xenetic Biosciences, Inc.
XBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -1.6% | 48.8% | 47.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -162% | -177.8% | -392% | -492.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -158.4% | -162.8% | -383.9% | -486.4% |
| EPS Diluted | -2.57 | -2.71 | -4.49 | -5.39 |
| % Growth | 5.2% | 39.6% | 16.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |